Skip to content

Treatment outcomes of reduced-dose ganciclovir injection

Efficacy and safety of reduced-dose intravitreal ganciclovir for treatment of cytomegalovirus retinitis (CMVR)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20160316001
Enrollment
Unknown
Registered
2016-03-16
Start date
2009-11-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CMVR lesion visual acuity intraocular pressure cytomegalovirus retinitis ganciclovir intravitreal injections treatment outcomes

Interventions

intravitreal injection of 2&#45
mg ganciclovir every week for 4 weeks and then every 2 weeks until resolution of CMVR lesion,intravenous injection of ganciclovir (10mg/kg/day) for 2 weeks then followed by intravitreal injection of 2
mg ganciclovir every week for 4 weeks and then every 2 weeks until resolution of CMVR lesion
Treatment,Treatment
IVTG,IVG+IVTG

Sponsors

Siriraj Development Research Fund (managed by Routine to Research:R2R)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with cytomegalovirus retinitis

Exclusion criteria

Exclusion criteria: patients with concomitant retinal inflammation patients who previously treated with ganciclovir

Design outcomes

Primary

MeasureTime frame
Resolution of CMVR lesion 24 weeks after medication Indirect ophthalmoscopic examination

Secondary

MeasureTime frame
change of visual acuity at resolution of lesion snellen visual acuity,incidence of complication during treatment clinical observation

Countries

Thailand

Contacts

Public ContactPitipol Choopong

Siriraj Hospital, Mahidol University

pitipol@gmail.com66868978654

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026